Rheumatoid Arthritis Therapeutics Market Size Analysis Report By Molecule Type, By Sales Channel (Prescription, OTC), And Segment Forecasts, 2018 - 2025

  • ID: 4479739
  • Report
  • 85 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • AbbVie.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb.
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson.
  • MORE
The global rheumatoid arthritis therapeutics market size is expected to reach USD 30.4 billion by 2025 expanding at a CAGR of 4.6% during the forecast period. Some of the key trends driving the market are availability of novel biologics, increase in potential clinical pipeline candidates, and rise in aging population. Thus, growing availability and awareness of safer drugs are projected to escalate market growth.

Rheumatoid arthritis affects approximately 1% of the global population. The condition has different symptoms such as joint pain, swelling, and stiffness, which are generally accompanied by chronic pain and inability to perform daily activities. Over a prolonged period, this disorder can hamper a patient’s mobility and can lead to permanent joint damage. If left untreated, this disorder can lead to mobility impairment and risk of joint replacement.

Growing prevalence of the disease, presence of biologics & biosimilars, and well-defined regulatory guidelines are poised to provide a fillip to the market. According to the Arthritis Foundation, 64% of the population within the age group of 65 is likely to suffer from arthritis in U.S. Increasing awareness regarding disease remittance therapies and rising healthcare expenditure in developed regions are estimated to promote revenue growth.

Current treatment for rheumatoid arthritis includes generic pharmaceuticals such as NSAIDs and corticosteroids along with novel biologics such as JAK inhibitors and IL-6 antagonists, which are widely used in developed countries due to their high effectiveness. New product launches such as Infliximab and Adalimumab biosimilars are anticipated to work in favor of the market. Moreover, Eli Lilly’s Olumiant and AbbVie’s Upadacitinib are expected to cut down chances of disease remittance.

Further key findings from the report suggest:
  • North America held 56.6% of the market in 2016 due to rising awareness regarding disease treatment, growing geriatric population, and high adoption of biopharmaceuticals for treatment
  • Due to growing popularity, the biopharmaceuticals segment is projected to exhibit a CAGR of 8.3% during the forecast period
  • Prescriptions are anticipated to emerge as more reliable and a preferred sales channel over the same period
  • Asia Pacific is the most promising region, registering a CAGR of 9.5% between 2017 and 2025
  • Some of the key players are AbbVie; Boehringer Ingelheim GmbH; Novartis AG; Regeneron Pharmaceuticals, Inc.; Pfizer, Inc.; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; UCB S.A.; Johnson & Johnson Services, Inc.; and Amgen, Inc.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie.
  • Amgen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb.
  • F. Hoffmann-La Roche AG
  • Johnson & Johnson.
  • MORE
Chapter 1 Research Methodology
1.1 Information Procurement
1.1.1 Purchased database
1.1.2 Internal database
1.2 Primary Research
1.2.1 List of primary sources include

Chapter 2 Executive Summary
2.1 Market Snapshot

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Well-defined reimbursement and regulatory framework in developed regions fuels the rheumatoid arthritis market
3.1.1.2 Improving treatment options for moderate-to-severe rheumatoid arthritis with second-line therapies
3.1.1.3 Reorientation of treatment approach from the relief of symptoms to targeted therapy to achieve disease remission
3.1.1.4 Compelling promotional campaign by leveraging digital platform
3.1.1.5 Increasing acceptance of large molecules biologics and biosimilars by rheumatologists
3.1.2 Market restraint analysis
3.1.2.1 Accessibility of the treatment
3.1.2.2 Patent expiration of blockbuster drugs
3.1.2.3 Alternative treatment options for rheumatoid arthritis sush arthroplasty .
3.2 Rheumatoid Arthritis Therapeutics - SWOT Analysis, by Factor (political & legal, economic, and technological)
3.3 Industry Analysis - Porter’s

Chapter 4 Global Rheumatoid Arthritis Therapeutics: Molecule Type Estimates & Trend Analysis
4.1 Global Rheumatoid Arthritis Therapeutics Market: Molecule Type Analysis
4.2 Pharmaceuticals
4.2.1 Pharmaceuticals molecule type market estimates and forecasts, 2014 - 2025 (USD Million)
4.3 Bio-pharmaceuticals
4.3.1 Bio-pharmaceuticals molecule type market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 5 Global Rheumatoid Arthritis Therapeutics: Sales Channel Type Estimates & Trend Analysis
5.1 Global Rheumatoid Arthritis Therapeutics Market: Sales Channel Type Analysis
5.2 Prescription
5.2.1 Prescription sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)
5.3 Over-the-Counter (OTC)
5.3.1 Over-the-Counter (OTC) sales channel segment market estimates and forecasts, 2014 - 2025 (USD Million)

Chapter 6 Global Rheumatoid Arthritis Therapeutics Market: Regional Estimates & Trend Analysis, by Molecule Type & Sales Channel
6.1 Global Rheumatoid Arthritis Therapeutics Market Share, by Region, 2015 & 2025
6.2 North America
6.2.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.2.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.2.3 U.S.
6.2.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.2.3.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
6.2.4 Canada
6.2.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.2.4.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
6.3 Europe
6.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.3.3 U.K.
6.3.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.3.3.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
6.3.4 Germany
6.3.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.3.4.2 Market estimates and forecasts, by sales channel, 2014 - 2025 (USD Million)
6.4 Asia Pacific
6.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.4.3 Japan
6.4.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.4.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.4.4 China
6.4.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.4.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.5 Latin America
6.5.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.5.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.5.3 Brazil
6.5.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.5.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.5.4 Mexico
6.5.4.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.5.4.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.6 MEA
6.6.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.6.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)
6.6.3 South Africa
6.6.3.1 Market estimates and forecasts, by molecule type, 2014 - 2025 (USD Million)
6.6.3.2 Market estimates and forecasts, by sales channel type, 2014 - 2025 (USD Million)

Chapter 7 Competitive Landscape
7.1 Company Profiles
7.1.1 AbbVie.
7.1.1.1 Company overview
7.1.1.2 Financial performance
7.1.1.3 Product benchmarking
7.1.1.4 Strategic initiatives
7.1.2 Boehringer Ingelheim GmbH
7.1.2.1 Company overview
7.1.2.2 Financial performance
7.1.2.3 Product benchmarking
7.1.2.4 Strategic initiatives
7.1.3 Novartis International AG
7.1.3.1 Company overview
7.1.3.2 Financial performance
7.1.3.3 Product benchmarking
7.1.3.4 Strategic initiatives
7.1.4 Regeneron Pharmaceuticals, Inc.
7.1.4.1 Company overview
7.1.4.2 Financial performance
7.1.4.3 Product benchmarking
7.1.4.4 Strategic initiatives
7.1.5 Pfizer Inc.
7.1.5.1 Company overview
7.1.5.2 Financial performance
7.1.5.3 Product benchmarking
7.1.5.4 Strategic initiatives
7.1.6 Bristol-Myers Squibb.
7.1.6.1 Company overview
7.1.6.2 Financial performance
7.1.6.3 Product benchmarking
7.1.6.4 Strategic initiatives
7.1.7 F. Hoffmann-La Roche AG
7.1.7.1 Company overview
7.1.7.2 Financial performance
7.1.7.3 Product benchmarking
7.1.7.4 Strategic initiatives
7.1.8 UCB S.A.
7.1.8.1 Company overview
7.1.8.2 Financial performance
7.1.8.3 Product benchmarking
7.1.8.4 Strategic initiatives
7.1.9 Johnson & Johnson.
7.1.9.1 Company overview
7.1.9.2 Financial performance
7.1.9.3 Product benchmarking
7.1.9.4 Strategic initiatives
7.1.10 Amgen Inc.
7.1.10.1 Company overview
7.1.10.2 Financial performance
7.1.10.3 Product benchmarking
7.1.10.4 Strategic initiatives

List of Tables

Table 1 North America rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 2 North America rheumatoid arthritis therapeutics market, by sales channel, 2014 - 2025 (USD Million)
Table 3 U.S. rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 4 U.S. rheumatoid arthritis therapeutics market, by sales channel, 2014 - 2025 (USD Million)
Table 5 Canada rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 6 Canada rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 7 Europe rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 8 Europe rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 9 Germany rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 10 Germany rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 11 U.K. rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 12 U.K. rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 13 Asia Pacific rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 14 Asia Pacific rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 15 Japan rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 16 Japan rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 17 China rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 18 China rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 19 Latin America rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 20 Latin America rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 21 Brazil rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 22 Brazil rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 23 Mexico rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 24 Mexico rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 25 MEA rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 26 MEA rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)
Table 27 South Africa rheumatoid arthritis therapeutics market, by molecule type, 2014 - 2025 (USD Million)
Table 28 South Africa rheumatoid arthritis therapeutics market, by sales channel type, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 SWOT Analysis, by Factor (political & legal, economic, and technological)
FIG. 10 Porter’s Five Forces Analysis
FIG. 11 Rheumatoid Arthritis Therapeutics Market: Molecule type outlook key takeaways
FIG. 12 Rheumatoid arthritis therapeutics market molecule type movement analysis (USD Mn)
FIG. 13 Global rheumatoid arthritis therapeutics market estimates and forecasts by pharmaceuticals molecule type, 2014 - 2025 (USD Million)
FIG. 14 Global rheumatoid arthritis therapeutics market estimates and forecasts by Bio-pharmaceuticals molecule type, 2014 - 2025 (USD Million)
FIG. 15 Rheumatoid Arthritis Therapeutics Market: sales channel type outlook key takeaways
FIG. 16 Rheumatoid arthritis therapeutics market sales channel segment movement analysis
FIG. 17 Global rheumatoid arthritis therapeutics market estimates and forecasts by prescription sales channel segment, 2014 - 2025 (USD Million)
FIG. 18 Global rheumatoid arthritis therapeutics market estimates and forecasts by Over-the-Counter (OTC) sales channel segment, 2014 - 2025 (USD Million)
FIG. 19 Regional market place: Key takeaways
FIG. 20 Rheumatoid arthritis therapeutics market regional outlook, 2015 & 2025
FIG. 21 North America rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 U.S. rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Canada rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Europe rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 Germany rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 U.K. rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 27 Asia Pacific rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 28 Japan rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 29 China rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 30 Latin America rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 31 Brazil rheumatoid arthritis therapeutics market estimates, and forecasts, 2014 - 2025 (USD Million)
FIG. 32 Mexico rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 33 MEA rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 34 South Africa rheumatoid arthritis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie.
  • Boehringer Ingelheim GmbH
  • Novartis International AG
  • Regeneron Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Bristol-Myers Squibb.
  • F. Hoffmann-La Roche AG
  • UCB S.A.
  • Johnson & Johnson.
  • Amgen Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll